A pre-pilot study on MRI CDM analysis for dementia

Conditions

Alzheimers disease, Frontotemporal lobar degeneration, No neurological disease

Gerard R. Ridgway, Takashi Nakajima, Mario Torso, Ian Hardingham, Pegah Khosropanah et al. (8 authors)

Alzheimer s & Dementia2025-12-01

Cortical Microstructure in AD Patients Treated with Lecanemab – Six‐Month Update on an Ongoing Real‐World Observational Study

Gerard R Ridgway, Takashi Nakajima, Mario Torso, Ian Hardingham, Pegah Khosropanah et al. (8 authors)

Alzheimer s & Dementia2025-12-01

10.1002/alz70856_107518

An exploratory pilot study on diffusion MRI measurement of cortical microstructural neurodegeneration for the assessment of dementia in a Japanese hospital setting

Gerard R. Ridgway, Takashi Nakajima, Mario Torso, Michele Valotti, Ian Hardingham et al. (7 authors)

Alzheimer s & Dementia2023-12-01

10.1002/alz.078706

An exploratory pilot study on diffusion MRI measurement of cortical microstructural neurodegeneration for the assessment of dementia in a Japanese hospital setting

Gerard R. Ridgway, Takashi Nakajima, Mario Torso, Michele Valotti, Ian Hardingham et al. (7 authors)

Alzheimer s & Dementia2023-12-01

10.1002/alz.081829

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 70 years or older with Alzheimer disease or frontotemporal lobar degeneration and patients aged 65 years or older with no neurological diseases such as lumbar spondylosis, cervical spondylosis, muscle contraction headache, hypertension, or hyperlipidemia who are attending the outpatient clinic of NHO Niigata National Hospital. 2. Patients who wish to undergo a brain MRI scan. 3. Patients who have been or will be assessed by a speech-language pathologist or clinical psychologist using MMSE-J and MoCA-J.

Exclusion criteria

Exclusion criteria: Patients who have been diagnosed with any neurodegenerative disease, cerebrovascular disease, and other severe diseases.

Design outcomes

Primary

Measure	Time frame
To confirm that MRI DTI30+, 3D T1 images and clinical data taken at a Japanese dementia clinic after the patient's IC are uploaded easily and safely to OBD in the UK for CDM analysis. (OBD stands for Oxford Brain Diagnostics Ltd that is a company registered in England and Wales. Registered No. 11703979 Oxford Centre for Innovation, New Road, Oxford, OX1 1BY)	—

Secondary

Measure	Time frame
To confirm that OBD can adjust and select the measurement parameters so that the CDM analysis is performed for disease and severity discriminant purposes using clinical data (age, gender, clinical diagnosis, disease duration, MMSE-J score, and MoCA-J score). To obtain information that will enable us to interpret CDM measurement parameters, and apply discriminant models, and discriminant formulae for use in the next pilot study, and to predict the number of cases in the next pilot study in order to validate further use of CDM.	—

Measure

Time frame

To confirm that OBD can adjust and select the measurement parameters so that the CDM analysis is performed for disease and severity discriminant purposes using clinical data (age, gender, clinical diagnosis, disease duration, MMSE-J score, and MoCA-J score). To obtain information that will enable us to interpret CDM measurement parameters, and apply discriminant models, and discriminant formulae for use in the next pilot study, and to predict the number of cases in the next pilot study in order to validate further use of CDM.

—

Contacts

Public ContactTakashi Nakajima

National Hospital Organization Niigata National Hospital

225-kenkyuu@mail.hosp.go.jp+81-257-30-8806

Outcome results